LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Anagliptin twice‐daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double‐blind, randomized controlled trial

Photo by explorenation from unsplash

To determine whether the twice‐daily (BID) regimen is superior to the once‐daily (QD) regimen for managing glycaemic variability by comparing the effects of anagliptin 100 mg BID versus sitagliptin 100 mg QD. Click to show full abstract

To determine whether the twice‐daily (BID) regimen is superior to the once‐daily (QD) regimen for managing glycaemic variability by comparing the effects of anagliptin 100 mg BID versus sitagliptin 100 mg QD.

Keywords: glycaemic variability; regimen improves; anagliptin twice; twice daily; daily regimen

Journal Title: Diabetes
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.